Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
Published Online: 2021-01-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alexandra Hogea•André Mattar•Antoinette R Tan•Christian Jackisch•Christian Schem•Daniil Stroyakovskii•Eleonora Restuccia•Jean-Yves Pierga•Kyung Hae Jung•Mahesh Shivhare•Michelino De Laurentiis•Ramon Colomer•Sarah Heeson•Seock-Ah Im•Tanja Badovinac Crnjevic•Whitney P Kirschbrown•Zbigniew Nowecki
